Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options
Mariem Znaidia, Caroline Demeret, Sylvie van der Werf, et al.
Viruses (2022) Vol. 14, Iss. 6, pp. 1247-1247
Open Access | Times Cited: 36

Showing 26-50 of 36 citing articles:

Bacteriophage–derived double-stranded RNA (larifan) exerts variable effects on human blood monocytes depending on age and sex of donors
R. Dovhyi, Mariia Rudyk, Tetiana Serhiichuk, et al.
The Ukrainian Biochemical Journal (2024) Vol. 96, Iss. 5, pp. 44-54
Open Access
A systems biology approach unveils different gene expression control mechanisms governing the immune response genetic program in peripheral blood mononuclear cells exposed to SARS-CoV-2
Damariz Marin, Geysson Javier Fernández, Juan C. Hernández, et al.
PLoS ONE (2024) Vol. 19, Iss. 12, pp. e0314754-e0314754
Open Access
Low-Dose Interferon I and III-Based Nasal Sprays: A Good-Looking COVID-19 Vaccine Candidate?
Theodor-Nicolae Carp, Michael Metoudi, Brent Brown, et al.
(2023)
Open Access | Times Cited: 1
Low-Dose Interferon I and III-Based Nasal Sprays: A Good-Looking COVID-19 Vaccine Candidate and a Therapy of the Future?
Theodor-Nicolae Carp, Michael Metoudi, Brent Brown, et al.
(2023)
Open Access | Times Cited: 1
Low-Dose Interferon I and III-Based Nasal Sprays: A Good-Looking COVID-19 Vaccine Candidate?
Theodor-Nicolae Carp, Michael Metoudi
(2022)
Open Access | Times Cited: 2
Immunomodulatory Agents for Coronavirus Disease-2019 Pneumonia
Dayna McManus, Matthew W. Davis, Alex Ortiz, et al.
Clinics in Chest Medicine (2022) Vol. 44, Iss. 2, pp. 299-319
Open Access | Times Cited: 1
Low-Dose Interferon I and Iii-Based Nasal Sprays: A Good-Looking Covid-19 Vaccine Candidate?
Theodor-Nicolae Carp, Michael Metoudi
(2022)
Open Access | Times Cited: 1
Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2
L. A. Oleinik, П. Г. Мадонов, М. Б. Пыхтина
Молекулярная биология (2023) Vol. 57, Iss. 2, pp. 307-315
Closed Access
Interferon lambda as a potential treatment for COVID-19
Matthew W. McCarthy
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 5, pp. 389-394
Closed Access
Organoids in COVID-19: can we break the glass ceiling?
Chiu Wang Chau, Ryohichi Sugimura
Journal of Leukocyte Biology (2023) Vol. 115, Iss. 1, pp. 85-99
Open Access
Macrophage Boolean networks in the time of SARS-CoV-2
Ugo Avila-Ponce de León, Osbaldo Resendis‐Antonio
Frontiers in Immunology (2022) Vol. 13
Open Access
Previous Page - Page 2

Scroll to top